Table 5.
Willingness for the second dose of COVID-19 Booster vaccination and associated factors among patients under 65 years (N = 614).
| Characteristics | Prevalence of inclination n/N (%) |
cOR (95%CI) | p-value | aOR (95%CI) | p-value |
|---|---|---|---|---|---|
| Individual-level variables Positive Attitude Scale | |||||
| Receiving a booster dose can maintain your antibody level and strengthen the protection against COVID-19 | |||||
| No (Strongly disagree or disagree or neutral) | 53/283 (18.7%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 165/331 (49.8%) | 4.313 (2.985, 6.234) | <0.001 | 4.805 (3.179, 7.262) | <0.001 |
| A booster dose is highly effective in protecting you from COVID-19 variants of concern (e.g., Omicron) | |||||
| No (Strongly disagree or disagree or neutral) | 62/332 (18.7%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 156/282 (55.3%) | 5.392 (3.753, 7.746) | <0.001 | 4.915 (3.320, 7.277) | <0.001 |
| A booster dose is highly effective in preventing severe consequences of COVID-19 | |||||
| No (Strongly disagree or disagree or neutral) | 62/317 (19.6%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 156/297 (52.5%) | 4.550 (3.178, 6.516) | <0.001 | 4.202 (2.844, 6.208) | <0.001 |
| Negative Attitude Scale | |||||
| The protection offered by COVID-19 vaccine booster dose is weaker among people with cancers | |||||
| No (Strongly disagree or disagree or neutral) | 69/223 (30.9%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 26/52 (50.0%) | 1.714 (1.139, 2.580) | 0.009 | 1.739 (1.103, 2.741) | 0.017 |
| Cancer therapy would reduce the protection of COVID-19 vaccine booster dose | |||||
| No (Strongly disagree or disagree or neutral) | 149/403 (37.0%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 69/211 (32.7) | 0.828 (0.583, 1.177) | 0.294 | 0.884 (0.602, 1.299) | 0.531 |
| The side effects of COVID-19 vaccine booster dose are more severe among people with cancers | |||||
| No (Strongly disagree or disagree or neutral) | 137/354 (38.7%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 81/260 (31.2%) | 0.717 (0.511, 1.006) | 0.053 | 0.841 (0.580, 1.219) | 0.361 |
| The duration of protection of COVID-19 vaccine booster dose is shorter among people with cancers | |||||
| No (Strongly disagree or disagree or neutral) | 147/401 (36.7%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 71/213 (33.3%) | 0.864 (0.609, 1.226) | 0.412 | 0.972 (0.662, 1.427) | 0.884 |
| COVID-19 vaccine booster dose would negatively affect the control of cancer | |||||
| No (Strongly disagree or disagree or neutral) | 68/161 (42.2%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 27/118 (22.9%) | 0.586 (0.416, 0.825) | 0.02 | 0.711 (0.489, 1.033) | 0.074 |
| Perceived subjective norm | |||||
| People who are important to you (e.g., family member, doctors) would support you to receive a booster dose | |||||
| No (Strongly disagree or disagree or neutral) | 122/332 (36.7%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 96/282 (34.0%) | 0.888 (0.637, 1.239) | 0.485 | 0.779 (0.540, 1.125) | 0.183 |
| Doctors would support you to uptake a booster | |||||
| No (Strongly disagree or disagree or neutral) | 130/476 (27.3%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 88/138 (63.8%) | 4.684 (3.136, 6.998) | <0.001 | 3.794 (2.432, 5.918) | <0.001 |
| Family member would support you to uptake a booster | |||||
| No (Strongly disagree or disagree or neutral) | 113/440 (25.7%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 105/174 (60.3%) | 4.404 (3.037, 6.385) | <0.001 | 4.237 (2.798, 6.416) | <0.001 |
| Perceived behavioral control | |||||
| Receiving a COVID-19 vaccine booster dose is easy for you if you want to | |||||
| No (Strongly disagree or disagree or neutral) | 125/327 (38.2%) | Reference | Reference | ||
| Yes (Strongly agree or agree) | 93/287 (32.4%) | 0.775 (0.555, 1.081) | 0.133 | 0.626 (0.432, 0.908) | 0.014 |
| Vaccination fatigue (tired of receiving COVID-19 vaccination over and over again) 133 | |||||
| No (Very unlikely or unlikely or neutral) | 180/519 (34.7%) | Reference | Reference | ||
| Yes (Very likely or likely) | 38/95 (40.0%) | 1.256 (0.802, 1.966) | 0.319 | 1.099 (0.671, 1.800) | 0.707 |
| Interpersonal variables Media Exposure Scale | |||||
| Infectivity of the Omicron variant of COVID-19 | |||||
| Almost never/seldom | 25/104 (24.0%) | Reference | Reference | ||
| Sometimes/always | 193/510 (37.8%) | 1.924 (1.186, 3.122) | 0.007 | 1.619 (0.956, 2.743) | 0.073 |
| Risk of having severe consequences or death is relatively low following infection of the COVID-19 | |||||
| Almost never/seldom | 53/193 (27.5%) | Reference | Reference | ||
| Sometimes/always | 165/421 (39.2%) | 1.703 (1.174, 2.469) | 0.005 | 1.470 (0.979, 2.205) | 0.063 |
| COVID-19 pandemic is not under control after COVID-19 vaccination rollout | |||||
| Almost never/seldom | 91/295 (30.8%) | Reference | Reference | ||
| Sometimes/always | 127/319 (39.8%) | 1.483 (1.062, 2.070) | 0.020 | 1.219 (0.844, 1.760) | 0.291 |
| Some people contract COVID-19 after completion of their primary vaccine series | |||||
| Almost never/seldom | 76/239 (31.8%) | Reference | Reference | ||
| Sometimes/always | 142/375 (37.9%) | 1.307 (0.928, 1.842) | 0.126 | 1.041 (0.710, 1.526) | 0.836 |
| Frequency of thoughtful consideration about veracity of COVID-19-specific information | |||||
| Almost never/seldom | 42/260 (16.2%) | Reference | Reference | ||
| Sometimes/always | 176/354 (49.7%) | 5.132 (3.473, 7.584) | <0.001 | 4.153 (2.716, 6.352) | <0.001 |
Statistically significant values are identified in boldface (p < 0.05); cOR, crude odds ratios; aOR, adjusted odds ratios, odds ratios adjusted for significant sociodemographic characteristics listed in Table 4 and incorporated together into the same model; CI, confidence interval.